Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Patient-Reported Outcomes Measurement Information System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Patient-Reported Outcomes Measurement Information System. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-001466-28 Sponsor Protocol Number: M15-656 Start Date*: 2017-08-07
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Inelig...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Trial now transitioned) FI (Trial now transitioned) SE (Completed) BE (Trial now transitioned) PT (Completed) DK (Completed) CZ (Trial now transitioned) AT (Completed) PL (Completed) FR (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000744-55 Sponsor Protocol Number: M15-954 Start Date*: 2020-10-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Hig...
    Medical condition: Myelodysplastic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000338-16 Sponsor Protocol Number: 42847922MDD3002 Start Date*: 2020-10-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Prematurely Ended) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003900-30 Sponsor Protocol Number: M16-043 Start Date*: 2017-06-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemi...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Prematurely Ended) DE (Completed) NO (Completed) GR (Completed) HU (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001685-38 Sponsor Protocol Number: 2693-CL-0312 Start Date*: 2021-11-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004701-11 Sponsor Protocol Number: MS200527_0073 Start Date*: 2020-01-10
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003233-38 Sponsor Protocol Number: WA41937 Start Date*: 2021-03-02
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
    Medical condition: Primary Membranous Nephropathy (pMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004980-36 Sponsor Protocol Number: MS200527-0082 Start Date*: 2020-09-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) LT (Completed) SK (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Prematurely Ended) NO (Prematurely Ended) ES (Completed) DE (Prematurely Ended) SI (Completed) IT (Prematurely Ended) RO (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003838-88 Sponsor Protocol Number: M13-494 Start Date*: 2018-09-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple ...
    Medical condition: R/R Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Trial now transitioned) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Restarted) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004972-20 Sponsor Protocol Number: MS200527ˍ0080 Start Date*: 2020-11-05
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) HU (Prematurely Ended) BE (Completed) CZ (Completed) BG (Completed) ES (Completed) FI (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000148-14 Sponsor Protocol Number: PLX108-10 Start Date*: 2015-06-03
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN
    Medical condition: Pigmented villonodular synovitis (PVNS) / giant cell tumour of tendon sheath (GCT-TS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062856 Giant cell tumour of tendon sheath benign LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Temporarily Halted) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000627-12 Sponsor Protocol Number: CV43140 Start Date*: 2021-06-01
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) PT (Prematurely Ended) DK (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004700-19 Sponsor Protocol Number: MS200527_0074 Start Date*: 2020-01-10
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001217-20 Sponsor Protocol Number: LPS16677 Start Date*: 2020-09-11
    Sponsor Name:Sanofi Aventis Recherche & Developpement
    Full Title: A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002846-33 Sponsor Protocol Number: KL13332020-104A Start Date*: 2022-10-13
    Sponsor Name:Abliva AB
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease
    Medical condition: Adult patients with primary mitochondrial disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10052637 Genetic mitochondrial abnormalities NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001389-39 Sponsor Protocol Number: VLX-601 Start Date*: 2022-04-19
    Sponsor Name:Mirum Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)
    Medical condition: Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003743-22 Sponsor Protocol Number: D9422C00001 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
    Medical condition: Crohn's Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005450-36 Sponsor Protocol Number: IM101-566 Start Date*: 2016-08-01
    Sponsor Name:Bristol-Myers Squibb Company
    Full Title: A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syn...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-004883-25 Sponsor Protocol Number: DCC-3014-03-001 Start Date*: 2022-05-16
    Sponsor Name:Deciphera Pharmaceuticals, LLC
    Full Title: A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)
    Medical condition: Tenosynovial Giant Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005186-13 Sponsor Protocol Number: CLNP023F12301 Start Date*: 2021-08-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
    Medical condition: atypical hemolytic uremic syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) SI (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 11:09:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA